{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,25]],"date-time":"2026-01-25T12:07:44Z","timestamp":1769342864334,"version":"3.49.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2021,7,12]],"date-time":"2021-07-12T00:00:00Z","timestamp":1626048000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,7,12]],"date-time":"2021-07-12T00:00:00Z","timestamp":1626048000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"crossref","award":["-"],"award-info":[{"award-number":["-"]}],"id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Appl Health Econ Health Policy"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1007\/s40258-021-00666-0","type":"journal-article","created":{"date-parts":[[2021,7,11]],"date-time":"2021-07-11T21:02:35Z","timestamp":1626037355000},"page":"929-940","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Cost-Effectiveness of Bosutinib for the Treatment of Adult Patients with Chronic Phase Chronic Myeloid Leukemia in the Second-Line Setting"],"prefix":"10.1007","volume":"19","author":[{"given":"B.","family":"Muresan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5321-561X","authenticated-orcid":false,"given":"C.","family":"Mamolo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. C.","family":"Cappelleri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. J.","family":"Postma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Heeg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,7,12]]},"reference":[{"key":"666_CR1","unstructured":"Leukaemia Foundation Australia website. Chronic myeloid leukemia. 2020. https:\/\/www.leukaemia.org.au\/disease-information\/leukaemias\/chronic-myeloid-leukaemia\/. Accessed 23rd Mar."},{"issue":"12","key":"666_CR2","doi-asserted-by":"publisher","first-page":"3123","DOI":"10.1002\/cncr.26679","volume":"118","author":"X Huang","year":"2012","unstructured":"Huang X, Cortes J, Kantarjian H. Estimations of the increasing prevalence and PLateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitors therapy. Cancer. 2012;118(12):3123\u20137.","journal-title":"Cancer"},{"key":"666_CR3","unstructured":"American Cancer Society website. Treating chronic myeloid leukemia by phase. 2020. https:\/\/www.cancer.org\/cancer\/chronic-myeloid-leukemia\/treating\/treating-by-phase.html. Accessed 23rd Mar 2020."},{"issue":"4","key":"666_CR4","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1182\/blood-2010-03-277152","volume":"117","author":"HM Kantarjian","year":"2011","unstructured":"Kantarjian HM, Giles FJ, Bhalla KN, et al. Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results. Blood. 2011;117(4):1141\u20135.","journal-title":"Blood"},{"issue":"15","key":"666_CR5","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1182\/blood-2013-10-532341","volume":"123","author":"NP Shah","year":"2014","unstructured":"Shah NP, Guilhot F, Cortes JE, et al. Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study. Blood. 2014;123(15):2317\u201324.","journal-title":"Blood"},{"issue":"17","key":"666_CR6","doi-asserted-by":"publisher","first-page":"4567","DOI":"10.1182\/blood-2011-05-355594","volume":"118","author":"JE Cortes","year":"2011","unstructured":"Cortes JE, Kantarjian HM, Br\u00fcmmendorf TH, et al. Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosom-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib. Blood. 2011;118(17):4567\u201376.","journal-title":"Blood"},{"key":"666_CR7","doi-asserted-by":"crossref","unstructured":"Cortes JE, Muresan B, Mamolo C, et al. Matching-adjusted indirect comparison of bosutinib, dasatinib and nilotinib effect on survival and major cytogenetic response in treatment of second-line chronic phase myeloid leukemia. Curr Med Res Opin. 2019; 35(9).","DOI":"10.1080\/03007995.2019.1605239"},{"key":"666_CR8","unstructured":"University of York Glossary. Partitioned Survival Model. 2019. https:\/\/yhec.co.uk\/glossary\/partitioned-survival-model\/. Accessed 4th Dec 2019."},{"issue":"7","key":"666_CR9","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.3390\/jcm9072251","volume":"9","author":"V Garc\u00eda-Guti\u00e9rrez","year":"2020","unstructured":"Garc\u00eda-Guti\u00e9rrez V, Hern\u00e1ndez-Boluda JC. Current treatment options for chronic myeloid leukemia patients failing second-generation tyrosine kinase inhibitors. J Clin Med. 2020;9(7):2251.","journal-title":"J Clin Med"},{"key":"666_CR10","doi-asserted-by":"crossref","unstructured":"Ongoren S, Eskazan AE, et al. Third-line treatment with second-generation tyrosine kinase inhibitors (dasatinib or nilotinib) in patients with chronic myeloid leukemia after two prior TKIs: real-life data on a single center experience along with the review of the literature. Hematology. 2018;23(4):212\u201320.","DOI":"10.1080\/10245332.2017.1385193"},{"key":"666_CR11","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1038\/s41375-020-0842-9","volume":"34","author":"A Hochhaus","year":"2020","unstructured":"Hochhaus A, Breccia M, et al. Expert opinion - management of chronic myeloid leukemia after resistance to second-generation tyrosine kinase inhibitors. Leukemia. 2020;34:1495\u2013502.","journal-title":"Leukemia"},{"issue":"12","key":"666_CR12","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1007\/s40273-015-0309-4","volume":"33","author":"JF O'Mahony","year":"2015","unstructured":"O\u2019Mahony JF, Newall AT, et al. Dealing with time in health economic evaluation: methodological issues and reccomendations for practice. Pharmacoeconomics. 2015;33(12):1255\u201368.","journal-title":"Pharmacoeconomics"},{"key":"666_CR13","doi-asserted-by":"crossref","unstructured":"Whitehead SJ, Ali S. Health outcomes in economic evaluation: the QALY and utilities. Br Med Bull. 2010; 96(1) (December 2010).","DOI":"10.1093\/bmb\/ldq033"},{"key":"666_CR14","unstructured":"Disutility [online]. York; York Health Economics Consortium; 2016. https:\/\/yhec.co.uk\/glossary\/disutility\/. Accessed Jan 2020."},{"issue":"1","key":"666_CR15","first-page":"107","volume":"35","author":"M Haacker","year":"2020","unstructured":"Haacker M, Hallett TB, et al. On discount rates for economic evaluations in global health. Health Policy Plan. 2020;35(1):107\u201314.","journal-title":"Health Policy Plan"},{"key":"666_CR16","doi-asserted-by":"crossref","unstructured":"Ramsey S, Wilke R, Briggs A, et al. Good research practices for cost-effectiveness analysis alongside clinical trials: the ISPOR RCT-CEA Task Force Report. Value Health. 2005;8(5).","DOI":"10.1111\/j.1524-4733.2005.00045.x"},{"key":"666_CR17","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.jval.2015.02.001","volume":"18","author":"SD Ramsey","year":"2015","unstructured":"Ramsey SD, Wilke RJ, Glick H, et al. Cost-effectiveness analysis alongside clinical trials II\u2014an ISPOR good research practices task force report. Value Health. 2015;18:161\u201372.","journal-title":"Value Health"},{"issue":"6","key":"666_CR18","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/j.jval.2012.05.004","volume":"15","author":"JE Signorovitch","year":"2012","unstructured":"Signorovitch JE, Sikirica V, Erder MH, et al. Matching-adjusted indirect comparisons: a new tool for timely comparative effectiveness research. Value Health. 2012;15(6):940\u20137.","journal-title":"Value Health"},{"issue":"2","key":"666_CR19","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1177\/0272989X17725740","volume":"38","author":"DM Phillippo","year":"2018","unstructured":"Phillippo DM, Ades AE, Dias S, et al. Methods for population-adjusted indirect comparisons in health technology appraisal. Med Decis Making. 2018;38(2):200\u201311.","journal-title":"Med Decis Making"},{"key":"666_CR20","first-page":"996","volume":"34","author":"A Hochhaus","year":"2020","unstructured":"Hochhaus A, Baccarani M, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020;34:996\u2013984.","journal-title":"Leukemia"},{"key":"666_CR21","doi-asserted-by":"crossref","unstructured":"Baccarani M, Castagnetti F, et al. Treatment recommendations for chronic myeloid leukemia. Mediterr J Hematol Infect Dis. 2014;6(1):e2014005.","DOI":"10.4084\/mjhid.2014.005"},{"key":"666_CR22","doi-asserted-by":"crossref","unstructured":"Hochhaus A, Saussele A, et al. Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(Supplement 4):iv41\u201351.","DOI":"10.1093\/annonc\/mdx219"},{"key":"666_CR23","unstructured":"Food and Drug Administration, USA. Highlights of prescribing information for bosutinib (FDA label). 2020. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/203341lbl.pdf. Accessed Jan 2020."},{"key":"666_CR24","unstructured":"Food and Drug Administration, USA. Highlights of prescribing information for nilotinib (FDA label). 2020. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/022068s004s005lbl.pdf. Accessed Jan 2020."},{"key":"666_CR25","unstructured":"Food and Drug Administration, USA. Highlights of prescribing information for dasatinib (FDA label). 2020. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/021986s020lbl.pdf. Accessed Jan 2020."},{"issue":"6","key":"666_CR26","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.3109\/10428194.2015.1091929","volume":"57","author":"C Chai-Adisaksopha","year":"2016","unstructured":"Chai-Adisaksopha C, Lam W, Hillis C. Major arterial events in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a meta-analysis. Leuk Lymphoma. 2016;57(6):1300\u201310.","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"666_CR27","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1111\/j.1524-4733.2009.00573.x","volume":"13","author":"SM Szabo","year":"2010","unstructured":"Szabo SM, Levy AR, Davis C, Holyoake TL, Cortes J. A multinational study of health state preference values associated with chronic myelogenous leukemia. Value Health. 2010;13(1):103\u201311.","journal-title":"Value Health."},{"key":"666_CR28","unstructured":"Tufts cost effectiveness analysis registry. 2020. http:\/\/healtheconomics.tuftsmedicalcenter.org\/cear4\/SearchingtheCEARegistry\/SearchtheCEARegistry.aspx. Accessed Jan 2020."},{"key":"666_CR29","unstructured":"Ara R. NICE DSU technical support document 12: the use of health state utility values in decision models. 2011. http:\/\/nicedsu.org.uk\/wp-content\/uploads\/2016\/03\/TSD12-Utilities-in-modelling-FINAL.pdf. Accessed Jun 2020."},{"key":"666_CR30","unstructured":"US Bureau of Labor Statistics. 2021. https:\/\/www.bls.gov\/cpi. Accessed Apr 2021."},{"key":"666_CR31","doi-asserted-by":"crossref","unstructured":"Rochau U, Kluibenschaedl M, Stenehjem D, et al. Effectiveness and cost-effectiveness of sequential treatment of patients with chronic myeloid leukemia in the United States: a decision analysis. Leuk Res Treat. 2015;2015:982395.","DOI":"10.1155\/2015\/982395"},{"issue":"11","key":"666_CR32","doi-asserted-by":"publisher","first-page":"2574","DOI":"10.1002\/cncr.20694","volume":"101","author":"SD Reed","year":"2004","unstructured":"Reed SD, Anstrom KJ, Ludmer JA, Glendenning GA, Schulman KA. Cost-effectiveness of imatinib versus interferon-alpha plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia. Cancer. 2004;101(11):2574\u201383.","journal-title":"Cancer"},{"key":"666_CR33","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/1472-6963-6-52","volume":"6","author":"E Fenwick","year":"2006","unstructured":"Fenwick E, Marshall DA, Levy AR, Nichol G. Using and interpreting cost-effectiveness acceptability curves: an example using data from a trial of management strategies for atrial fibrillation. BMC Health Serv Res. 2006;6:52.","journal-title":"BMC Health Serv Res"},{"issue":"19","key":"666_CR34","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1056\/NEJMoa1306494","volume":"369","author":"JE Cortes","year":"2013","unstructured":"Cortes JE, Kim DW, Pinilla-Ibarz J, et al. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med. 2013;369(19):1783\u201396.","journal-title":"N Engl J Med"},{"key":"666_CR35","unstructured":"Latimer N. NICE DSU Technical Support Document 14: Survival Analysis for Economic Evaluations alongside Clinical Trials\u2014Extrapolation with Patient-Level Data. Report by The Decisions Support Unit; 2011."},{"key":"666_CR36","doi-asserted-by":"publisher","first-page":"118","DOI":"10.2471\/BLT.14.138206","volume":"93","author":"E Marseille","year":"2015","unstructured":"Marseille E, Larson B, et al. Thresholds for the cost-effectiveness of interventions: alternative approaches. Bull World Health Organ Policy Pract. 2015;93:118\u201324.","journal-title":"Bull World Health Organ Policy Pract"},{"key":"666_CR37","doi-asserted-by":"crossref","unstructured":"Dubois RW. Cost-effectiveness thresholds in the USA: are they coming? Are they already here? J Comp Eff Res. 2015;5(1).","DOI":"10.2217\/cer.15.50"},{"issue":"9","key":"666_CR38","doi-asserted-by":"publisher","first-page":"A433","DOI":"10.1016\/j.jval.2017.08.201","volume":"20","author":"T Ward","year":"2017","unstructured":"Ward T, Jones B, Harrison JP, et al. The clinical and cost effectiveness of Dasatinib versus Nilotinib for the first and second line treatment of people with chronic myeloid Leukaemia. Value Health. 2017;20(9):A433.","journal-title":"Value Health"},{"issue":"29","key":"666_CR39","doi-asserted-by":"publisher","first-page":"7445","DOI":"10.1097\/MD.0000000000007445","volume":"96","author":"B Wu","year":"2017","unstructured":"Wu B, Liu M, Li T, et al. An economic analysis of high-dose imatinib, dasatinib, and nilotinib for imatinib-resistant chronic phase chronic myeloid leukemia in China. Medicine (Baltimore). 2017;96(29):7445.","journal-title":"Medicine (Baltimore)"},{"issue":"8","key":"666_CR40","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1016\/j.jval.2011.07.006","volume":"14","author":"M Hoyle","year":"2011","unstructured":"Hoyle M, Rogers G, Moxham T, et al. Cost-effectiveness of Dasatinib and Nilotinib for Imatinib-resistant or -intolerant chronic phase chronic myeloid leukemia. Value Health. 2011;14(8):1057\u201367.","journal-title":"Value Health"},{"key":"666_CR41","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/s40273-015-0327-2","volume":"34","author":"P Vemer","year":"2016","unstructured":"Vemer P, Ramos IC, van Voorn GAK, et al. AdViSHE: a validation-assessment tool of health-economic models for decision makers and model users. Pharmacoeconomics. 2016;34:349\u201361.","journal-title":"Pharmacoeconomics"}],"container-title":["Applied Health Economics and Health Policy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40258-021-00666-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40258-021-00666-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40258-021-00666-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,25]],"date-time":"2021-10-25T12:42:58Z","timestamp":1635165778000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40258-021-00666-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,12]]},"references-count":41,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["666"],"URL":"https:\/\/doi.org\/10.1007\/s40258-021-00666-0","relation":{},"ISSN":["1175-5652","1179-1896"],"issn-type":[{"value":"1175-5652","type":"print"},{"value":"1179-1896","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,12]]},"assertion":[{"value":"4 June 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was sponsored by Pfizer Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"C. Mamolo and J.C. Cappelleri are employees and shareholders of Pfizer Inc. B. Muresan and B. Heeg are employees of Ingress-Health BV, and were paid consultants to Pfizer in connection with the development of this article, which provides consulting and other research services to pharmaceutical, medical device, and related organizations. In their salaried positions, they work with a variety of companies and organizations, and are precluded from receiving payment or honoraria directly from these organizations for services rendered. B. Heeg is also an equity holder of Ingress-Health. M.J. Postma received grants and honoraria from various pharmaceutical companies, including those developing, producing, and marketing the drugs included in this paper. Also, M.J. Postma is advisor to Asc Academics and holds stocks in Pharmacoeconomics Advice Groningen, Health-Ecore and Ingress-Health; the latter company was paid by Pfizer Inc. to conduct this study and develop this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Visual Basic code used for PSA and DSA programming is available on request.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Conception and design of the work\u2014BM, CM, JCC, BH; acquisition and analysis of the data\u2014BM, CM, JCC, BH; interpretation of the data\u2014BM, CM, JCC, MJP, BH; drafting the work and revising it for important intellectual content\u2014BM, CM, JCC, MJP, BH; final approvals for publication and agreement to be accountable for all aspects of the work\u2014BM, CM, JCC, MJP, BH.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contribution"}},{"value":"Available on request (stored on password-protected external hard drives).","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}}]}}